MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

Is Bristol Myers Squibb's New Multiple Myeloma Drug a Game Changer

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is Bristol Myers Squibb's Deucravacitinib a Game-Changer for SLE Patients and BMY Investors

3 weeks ago

Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now

2 months ago

Why Are Barclays Analysts Bullish on Eli Lilly and Bristol-Myers Squibb

2 months ago

Is Roche's Fenebrutinib a Game Changer for Multiple Sclerosis Treatment

2 months ago

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic

B7-H3 has emerged as a primary target in oncology research, with a new natural killer (NK) cell engager entering clinical trials. This development marks a shift in cancer drug development toward this ...

GTBP

Stock News•3 weeks ago

Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

Pfizer’s ELREXFIO demonstrated a statistically significant improvement in progression-free survival for patients with relapsed or refractory multiple myeloma in the Phase 3 MagnetisMM-5 study. These p...

PFE

Stock News•3 weeks ago

There's a Revolution in Cancer. But Can Big Pharma Afford It?

Revolution Medicines shares surged following positive developments for its pancreatic-cancer drug candidate. Despite market speculation, a near-term acquisition appears unlikely, suggesting investors ...

RVMD

Stock News•3 weeks ago

Bristol-Myers Squibb: 'Strong Buy' As 2026 Milestones Could Bolster Its Prospects

Bristol-Myers Squibb's growth portfolio rose 16% YoY and now accounts for nearly 60% of total revenue. This expansion helps offset impending patent cliff losses as the company advances key pipeline as...

BMY